Heptares Therapeutics
Oliver Schlenker has a diverse work experience in the field of scientific research. Oliver started their career at the National Institute for Medical Research in Mill Hill, London, where they worked as a Postdoctoral Fellow from 2006 to 2009. After their time there, they joined Sosei Heptares in 2010 as a Senior Research Scientist, where they made significant contributions until 2015. Oliver then took on the role of Senior Research Scientist II at Sosei Heptares and continued to excel until 2022. Currently, they are serving as a Principal Scientist at Sosei Heptares.
Oliver Schlenker obtained their PhD in Structural Biology from Ruprecht-Karls-Universität Heidelberg in Germany, from 2001 to 2006. During the same period, they also completed their Diploma Thesis in Biochemistry at Leibniz Universität Hannover in Germany.
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.